drugset / Trial / NCT03418324
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.
Timeline
- Start
- 2018-03-05
- Primary completion
- 2019-11-06
- Completion
- 2019-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | 15 mg/kg | — |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |